These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33087662)

  • 21. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ABVD plus rituximab
    Strati P; Fanale MA; Oki Y; Turturro F; Fayad LE; Bartlett NL; Gladstone DE; Kasamon YL; Portlock CS; Wilson WH; Goy A; Younes A; Lee HJ
    Haematologica; 2019 Feb; 104(2):e65-e67. PubMed ID: 30190343
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
    Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
    J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
    Arakelyan N; Jais JP; Tomowiack C; Colombat P; Berthou C; Desablens B; Moles-Moreau MP; Gastinne T; Quittet P; Casassus P; Le Pourhiet-Le Mevel A; Ghandour C; Brière J; Colonna P; Andrieu JM
    Leuk Lymphoma; 2013 Jan; 54(1):76-82. PubMed ID: 22680774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI ) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma.
    Russo F; Corazzelli G; Frigeri F; Capobianco G; Aloj L; Volzone F; De Chiara A; Bonelli A; Gatani T; Marcacci G; Donnarumma D; Becchimanzi C; de Lutio E; Ionna F; De Filippi R; Lastoria S; Pinto A
    Br J Haematol; 2014 Jul; 166(1):118-29. PubMed ID: 24673727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials.
    Sasse S; Bröckelmann PJ; Goergen H; Plütschow A; Müller H; Kreissl S; Buerkle C; Borchmann S; Fuchs M; Borchmann P; Diehl V; Engert A
    J Clin Oncol; 2017 Jun; 35(18):1999-2007. PubMed ID: 28418763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial.
    Phillips T; Migliaccio-Walle K; Yu KS; Bloudek B; Liu N; Fanale M; Burke JM
    Leuk Lymphoma; 2023 May; 64(5):1017-1025. PubMed ID: 37074674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma.
    Hartridge-Lambert SK; Schöder H; Lim RC; Maragulia JC; Portlock CS
    Cancer; 2013 Mar; 119(6):1203-9. PubMed ID: 23132361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.
    Bhethanabhotla S; Jain S; Kapoor G; Mahajan A; Chopra A; Vishnubhatla S; Bakhshi S
    Leuk Lymphoma; 2017 Jul; 58(7):1617-1623. PubMed ID: 27919174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma.
    D'Arco AM; Califano C; Barone L; Belsito Petrizzi V; Iovino V; Langella M; Maglione V; Rivellini F; De Lorenzo S
    Br J Haematol; 2015 Nov; 171(4):662-5. PubMed ID: 25873239
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment strategy for newly diagnosed classical Hodgkin lymphoma: current achievements using interim PET-guided therapy].
    Kusumoto S
    Rinsho Ketsueki; 2020; 61(9):1244-1251. PubMed ID: 33162522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
    Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
    JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
    Borchmann P
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):65-74. PubMed ID: 24287068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABVD versus stanford V versus MEC in unfavourable Hodgkin's lymphoma: results of a randomised trial.
    Chisesi T; Federico M; Levis A; Deliliers GL; Gobbi PG; Santini G; Luminari S; Linfomi MB;
    Ann Oncol; 2002; 13 Suppl 1():102-6. PubMed ID: 12078888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy.
    Chand VK; Link BK; Ritchie JM; Shannon M; Wooldridge JE
    Leuk Lymphoma; 2006 Apr; 47(4):657-63. PubMed ID: 16690524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence.
    Seshachalam A; Karpurmath SV; Rathnam K; Raman SG; Janarthinakani M; Prasad K; Patil C; Anoop P; Reddy N; Anumula SK; Roopa SP; Golamari KR; Danthala M; Gunari P; Malipatil B; Rangarajan B; Udupa KS; Nandennavar M; Niraimathi K; Shewade HD
    J Glob Oncol; 2019 Nov; 5():1-13. PubMed ID: 31834832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?
    Milgrom SA; Pinnix CC; Chuang H; Oki Y; Akhtari M; Mawlawi O; Garg N; Gunther JR; Reddy JP; Smith GL; Rohren E; Hagemeister FB; Lee HJ; Fayad LE; Dong W; Osborne EM; Abou Yehia Z; Fanale M; Dabaja BS
    Br J Haematol; 2017 Nov; 179(3):488-496. PubMed ID: 28832956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry.
    Nguyen J; Wellard C; Chung E; Cheah CY; Dickinson M; Doo NW; Keane C; Talaulikar D; Berkahn L; Morgan S; Hamad N; Cochrane T; Johnston AM; Forsyth C; Opat S; Barraclough A; Mutsando H; Ratnasingam S; Giri P; Wood EM; McQuilten ZK; Hawkes EA;
    Eur J Haematol; 2023 Apr; 110(4):386-395. PubMed ID: 36539351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.